Mechanically stable rifampin antibiotic cement inhibits Pseudomonas aeruginosa biofilm surface growth
Journal of Orthopaedic Research · 2024-03 · 42 (3) · 547-554
DOI: 10.1002/jor.25720 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Orthopaedic Research, online erschienen am 04.11.2023. Verfasst von Jacob Laperche und 6 weiteren Autor:innen. Beteiligte Einrichtung: Joint Replacement Center, University Orthopedics, East Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Prosthesis-Related Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Brown University Department of Orthopedics Resident Research Funds.
Abstract (Originalsprache)
Rifampin has been proven to be effective in the treatment of prosthetic infections due to its ability to intercalate into biofilms. The use of rifampin in antibiotic spacers is not well described, which would be especially important in the local periprosthetic environment where parenteral doses have poor penetration. The null hypothesis tests if rifampin use in polymethyl methacrylate (PMMA) cement will show no clinically significant impact on mechanical strength at antibiotic concentrations that remain bactericidal. Test antibiotic cement samples supplemented with 0, 30, 50, 100, 150, or 200 mg of rifampin into a standard 40 g bag were tested for compression to failure using published ASTM standards. The samples were then inoculated with Pseudomonas aeruginosa and either evaluated for lipopolysaccharide (LPS) presence as a marker of biofilm or tested by elution as the Kirby Bauer assay. Rifampin concentrations of 30 and 50 mg, showed no statistically different mechanical characteristics from control PMMA ( p > 0.05). The 100‐mg sample fell within the acceptable range of compressive strength and had significantly less LPS and bacterial presence compared to the control at 12 and 24 h. The ability of PMMA with 100 mg of rifampin to maintain its structural integrity and have significant bacterial inhibition at 12 and 24 h makes it a great candidate as an antibiotic bone cement additive. PMMA loaded with up to 100 mg of rifampin shows promise in the treatment and prevention of periprosthetic joint infection for total knee and total hip arthroplasty.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Joint Replacement Center, University Orthopedics, East Providence, Rhode Island, USA.
- Frank H. Netter School of Medicine, Quinnipiac University, North Haven, Connecticut, USA.
- Department of Orthopedic Surgery, Rhode Island Hospital, Providence, Rhode Island, USA.
- Department of Orthopedic Surgery, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
ORCID-Profile: Dioscaris R Garcia, Valentin Antoci
Förderung
- Brown University Department of Orthopedics Resident Research Funds
Zitieren
APA
Laperche, J., Barrett, C. C., Boduch, A., Glasser, J., Clippert, D., Garcia, D. R., & Antoci, V. (2024). Mechanically stable rifampin antibiotic cement inhibits Pseudomonas aeruginosa biofilm surface growth. Journal of Orthopaedic Research, 42(3), 547-554. https://doi.org/10.1002/jor.25720
Vancouver
Laperche J, Barrett CC, Boduch A, Glasser J, Clippert D, Garcia DR, et al. Mechanically stable rifampin antibiotic cement inhibits Pseudomonas aeruginosa biofilm surface growth. Journal of Orthopaedic Research. 2024;42(3):547-554. doi:10.1002/jor.25720
BibTeX
@article{Laperche2024,
author = {Laperche, Jacob and Barrett, Caitlin C and Boduch, Abigail and Glasser, Jillian and Clippert, Drew and Garcia, Dioscaris R and Antoci, Valentin},
title = {Mechanically stable rifampin antibiotic cement inhibits Pseudomonas aeruginosa biofilm surface growth},
journal = {Journal of Orthopaedic Research},
year = {2024},
volume = {42},
number = {3},
pages = {547--554},
doi = {10.1002/jor.25720}
}
EUVIMED